<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/07733234-E676-4AC2-BC37-BC55833A4789"><gtr:id>07733234-E676-4AC2-BC37-BC55833A4789</gtr:id><gtr:name>Biosceptre (UK) Limited</gtr:name><gtr:address><gtr:line1>JONAS WEBB BUILDING 
BABRAHAM RESEARCH BUILDING</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/07733234-E676-4AC2-BC37-BC55833A4789" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>07733234-E676-4AC2-BC37-BC55833A4789</gtr:id><gtr:name>Biosceptre (UK) Limited</gtr:name><gtr:address><gtr:line1>JONAS WEBB BUILDING 
BABRAHAM RESEARCH BUILDING</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>99592.0</gtr:offerGrant><gtr:projectCost>165987.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4F47AD81-3AF8-4DA1-975C-7A675B6BD95A"><gtr:id>4F47AD81-3AF8-4DA1-975C-7A675B6BD95A</gtr:id><gtr:firstName>Romain</gtr:firstName><gtr:surname>Lara</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710832"><gtr:id>9A7FB5C0-38FD-4A1B-AF49-D26841CE25B0</gtr:id><gtr:title>Proof of concept for nf-P2X7 to treat and diagnose cancers</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710832</gtr:grantReference><gtr:abstractText>This project will deliver proof of concept (POC) data to identify a new diagnostic and to
establish Kidney and lung cancer as therapeutic targets for BIL03s, our lead fully human
therapeutic antibody. The World Health Organization reported that 8.2 million died of cancer
in 2012. While progress has been made, patient outcomes remain poor particularly for kidney
and lung cancer, existing treatments and those in development are inadequate. Biosceptre is
an established UK company developing cancer therapeutics, its goal is to commercialise
therapeutics and diagnostics to target nf-P2X7, a unique variant of the P2X7 receptor present
at the surface of cancerous but not normal cells. Biosceptre has established freedom to operate
and has a strong global patent portfolio. Antibodies targeting nf-P2X7 have shown specificity
and efficacy in pre-clinical studies. Toxicology studies have confirmed they are safe. Hence,
nf-P2X7 can be targeted safely and effectively. Our aims are to define the potential for
efficacy in kidney and lung cancer indications using ?gold standard? patient derived
xenografts (PDXs) models and to establish the potential for developing a companion
diagnostic to define responding patient populations.
Biosceptre will establish breadth of utility for BIL03s by obtaining efficacy data against a
range of cancers and by analysing the correlation between BIL03s efficacy in patient derived
tumour xenograft models (PDX) and P2X7 expression status. This will define the market for
BIL03s and establish POC for a companion diagnostic. This approach will have a critical
impact on the commercial viability of BIL03s by increasing the number of cancer indications
targeted and facilitating selection of patient cohorts based on their P2X7 expression status.
This project will foster academic collaborations and lead to publications. Biosceptre will also
undertake business development activities to establish the commercial and clinical pathways
for BIL03s development.</gtr:abstractText><gtr:fund><gtr:end>2017-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2016-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>99592</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710832</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>